BrownJ., HuntL., VitesN., ShortC., GokalR., MallickN.Comparative mortality from cardiovascular disease in patients with chronic renal failure.Nephrol Dial Transplant1994; 9: 1136–42.
2.
LameireN., BernaertP., LambertM., VijtD.Cardiovascular risk factors and their management in patients on continuous ambulatory peritoneal dialysis.Kidney Int Suppl1994; 48: S31–8.
3.
BurrellD., AntignaniA., FeinP., GoldwasserP., MittmanN., AvramM.Longitudinal survey of apolipoproteins and atherogenic risk in hemodialysis and continuous ambulatory peritoneal dialysis patients.ASAIO Trans1990; 36: 331–5.
4.
MaK., GreeneE., RaijL.Cardiovascular risk factors in chronic renal failure and hemodialysis populations.Am J Kidney Dis1992; 19: 505–13.
5.
AvramM., FeinP., AntignaniA., MittmanN., MushnickR., LustigA.Cholesterol and lipid disturbances in renal disease: The natural history of uremic dyslipidemia and the impact of hemodialysis and continuous ambulatory peritoneal dialysis.Am J Med1989; 87: 55–60.
6.
AppelG.Lipid abnormalities in renal disease.Kidney Int1991; 39: 169–83.
7.
KronenbergF., KönigP., NeyerU., AuingerM., PrisbasnigA., LangU.Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis.J Am Soc Nephrol1995; 6: 110–20.
8.
CressmanM., HeykaR., PaganiniE., O'NeilJ., SkibinskiC., HoffH.Lipoprotein (a) is an independent risk factor for cardiovascular disease in hemodialysis patients.Circulation1992; 86: 475–82.
ZenkerG., KoltringerP., BoneG., NiederkornK., PfeifferK., JurgensG.Lipoprotein (a) as a strong indicator for cerebrovascular disease.Stroke1989; 17: 942–5.
11.
TeruelJ., MarcénR., Navarro–AntolínJ., AguileraA., Fernández–JuárezG., OrtuñoJ.Androgen versus erythropoietin for the treatment of anemia in hemodialyzed patients: A prospective study.J Am Soc Nephrol1996; 7: 140–4.
12.
NavarroJ., MoraC., RiveroA., MacíaM., GallegoE., ChahinJ.Androgens for the treatment of anemia in peritoneal dialysis patients.Adv Perit Dial1998; 14: 232–5.
13.
NavarroJ.F., MoraC.Effect of androgens on anemia and malnutrition in renal failure: Implications for patients on peritoneal dialysis.Perit Dial Int2001; 21: 14–24.
14.
TeruelJ., AguileraA., MarcénR., NavarroJ., GarcíaG., OrtuñoJ.Androgen therapy for anaemia of chronic renal failure. Indications in the erythropoietin era.Scand J Urol Nephrol1996; 30: 403–8.
15.
GlazerG., SuchmanA.L.Lack of demonstrated effect of nandrolone on serum lipids.Metabolism1994; 43: 204–10.
